Table 2: Clinical and parasitological therapeutic outcome after PCR correction.
|
AL |
ASMQ |
DHAP |
P (1) |
P (2) |
|||
Per-protocol day 28 |
|
|
|
|
|
|
|
|
|
Before PCR corrections (%) |
After PCR corrections (%) |
Before PCR corrections (%) |
After PCR corrections (%) |
Before PCR corrections (%) |
After PCR corrections (%) |
|
|
ETF |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
|
|
LCF |
2 (2.9) |
1 (1.4) |
4 (5.7) |
2 (2.9) |
1 (1.4) |
1 (1.4) |
|
|
LPF |
7 (10.1) |
1 (1.4) |
3 (4.3) |
0 (0.0) |
4 (5.7) |
0 (0.0) |
|
|
ACPR (N; IC95%)* |
60 (86.9) (IC95%; 85.3-88.5%) |
67 (97.1) (IC95% 96.8-97.4%) |
63 (90.0) (IC95%; 88.8-91.2%) |
68 (97.1) (IC95%; 96.8-97.4%) |
65 (92.9) (IC95%; 92.1-93.7%) |
69 (98.6) (IC95%; 98.4-98.8%) |
0.002 |
0.002
|
Total |
69 |
69 |
70 |
70 |
70 |
70 |
|
|
Per-protocol day 42 |
|
|
|
|
|
|
|
|
LCF |
4 (6.0) |
1 (1.4) |
0 (0.0) |
0 (0.0) |
1 (1.4) |
0 (0.0) |
|
|
LPF |
9 (13.0) |
3 (4.5) |
11 (16.8) |
2 (2.9) |
5 (7.2) |
0 (0.0) |
|
|
ACPR (N; IC95%)* |
56 (81.1) (IC95% 78.8-83.4%) |
65 (94.2) (IC95%; 93.5-94.9%) |
57 (83.8) (IC95%; 81.8-85.8%) |
66 (97.1)(IC95%; 96.8-97.4%) |
63 (91.3) (IC95%; 90.3-92.3%) |
70 (100) |
0.01 |
0.003 |
Total |
69 |
69 |
68 |
68 |
70 |
70 |
|
|
ACPR D7-D42 |
84% (IC 95%; 83.3- 84.7%) |
95.6% (IC95%; 95.3-96.0%) |
86.9% (IC95%; 86.1-87.7%) |
97.1% (IC95%; 96.8-97.4%) |
92.1% (IC95%; 91.9-92.3%) |
99.3% (IC95%; 99.1-99.6%) |
0.004 |
0.003 |
Per-protocol efficacy: Proportion of adequate clinical and parasitological response; *Confidence interval at 95 % (binomial exact method); (1) Compare DHAP vs. AL; (2) Compare DHAP vs. ASMF.